MPDL3280A and Stereotactic Ablative Radiotherapy in Patients With Non-small Cell Lung Cancer

NCT02400814 · clinicaltrials.gov ↗

PHASE1

Phase

TERMINATED

Status

27

Enrollment

OTHER

Sponsor class

Stopped Enrollment halted due to slow accrual.

Conditions

Recurrent Non-Small Cell Lung Carcinoma
Stage IV Non-Small Cell Lung Cancer

Interventions

DRUG: Anti-PD-L1 Monoclonal Antibody MPDL3280A
RADIATION: Stereotactic Body Radiation Therapy

Sponsor

Megan Daly, MD

Collaborators

[object Object]
[object Object]